These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 38305989)

  • 1. Muscarinic control of cardiovascular function in humans: a review of current clinical evidence.
    Palma JA
    Clin Auton Res; 2024 Feb; 34(1):31-44. PubMed ID: 38305989
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective allosteric modulation of muscarinic acetylcholine receptors for the treatment of schizophrenia and substance use disorders.
    Teal LB; Gould RW; Felts AS; Jones CK
    Adv Pharmacol; 2019; 86():153-196. PubMed ID: 31378251
    [TBL] [Abstract][Full Text] [Related]  

  • 3. M1 muscarinic acetylcholine receptors: A therapeutic strategy for symptomatic and disease-modifying effects in Alzheimer's disease?
    Scarpa M; Hesse S; Bradley SJ
    Adv Pharmacol; 2020; 88():277-310. PubMed ID: 32416870
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of central muscarinic-1 receptor stimulation on blood pressure regulation.
    Medina A; Bodick N; Goldberger AL; Mac Mahon M; Lipsitz LA
    Hypertension; 1997 Mar; 29(3):828-34. PubMed ID: 9052903
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Effectiveness of Muscarinic Receptor-Targeted Interventions in Neuropsychiatric Disorders: A Systematic Review.
    Vaidya S; Guerin AA; Walker LC; Lawrence AJ
    CNS Drugs; 2022 Nov; 36(11):1171-1206. PubMed ID: 36269510
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Muscarinic M1 and/or M4 receptor agonists as potential novel treatments for psychoses].
    Spoelstra SK; Visser L; Knegtering H
    Tijdschr Psychiatr; 2023; 65(9):555-562. PubMed ID: 37947466
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Opportunities and challenges for the development of M
    Nguyen HTM; van der Westhuizen ET; Langmead CJ; Tobin AB; Sexton PM; Christopoulos A; Valant C
    Br J Pharmacol; 2024 Jul; 181(14):2114-2142. PubMed ID: 36355830
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Positive allosteric modulation of M
    Yohn SE; Conn PJ
    Neuropharmacology; 2018 Jul; 136(Pt C):438-448. PubMed ID: 28893562
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline-trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial.
    Kaul I; Sawchak S; Correll CU; Kakar R; Breier A; Zhu H; Miller AC; Paul SM; Brannan SK
    Lancet; 2024 Jan; 403(10422):160-170. PubMed ID: 38104575
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Subtype-selective allosteric modulators of muscarinic receptors for the treatment of CNS disorders.
    Conn PJ; Jones CK; Lindsley CW
    Trends Pharmacol Sci; 2009 Mar; 30(3):148-55. PubMed ID: 19201489
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Xanomeline and the antipsychotic potential of muscarinic receptor subtype selective agonists.
    Mirza NR; Peters D; Sparks RG
    CNS Drug Rev; 2003; 9(2):159-86. PubMed ID: 12847557
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Muscarinic Acetylcholine Receptor M
    Bender AM; Garrison AT; Lindsley CW
    ACS Chem Neurosci; 2019 Mar; 10(3):1025-1034. PubMed ID: 30280567
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Allosteric modulators targeting CNS muscarinic receptors.
    Bock A; Schrage R; Mohr K
    Neuropharmacology; 2018 Jul; 136(Pt C):427-437. PubMed ID: 28935216
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Allosteric modulation of the M1 muscarinic acetylcholine receptor: improving cognition and a potential treatment for schizophrenia and Alzheimer's disease.
    Melancon BJ; Tarr JC; Panarese JD; Wood MR; Lindsley CW
    Drug Discov Today; 2013 Dec; 18(23-24):1185-99. PubMed ID: 24051397
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Crystal structures of the M1 and M4 muscarinic acetylcholine receptors.
    Thal DM; Sun B; Feng D; Nawaratne V; Leach K; Felder CC; Bures MG; Evans DA; Weis WI; Bachhawat P; Kobilka TS; Sexton PM; Kobilka BK; Christopoulos A
    Nature; 2016 Mar; 531(7594):335-40. PubMed ID: 26958838
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interaction of neuromuscular blocking drugs with recombinant human m1-m5 muscarinic receptors expressed in Chinese hamster ovary cells.
    Cembala TM; Sherwin JD; Tidmarsh MD; Appadu BL; Lambert DG
    Br J Pharmacol; 1998 Nov; 125(5):1088-94. PubMed ID: 9846649
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting Muscarinic Acetylcholine Receptors for the Treatment of Psychiatric and Neurological Disorders.
    Moran SP; Maksymetz J; Conn PJ
    Trends Pharmacol Sci; 2019 Dec; 40(12):1006-1020. PubMed ID: 31711626
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective allosteric enhancement of the binding and actions of acetylcholine at muscarinic receptor subtypes.
    Birdsall NJ; Farries T; Gharagozloo P; Kobayashi S; Kuonen D; Lazareno S; Popham A; Sugimoto M
    Life Sci; 1997; 60(13-14):1047-52. PubMed ID: 9121346
    [TBL] [Abstract][Full Text] [Related]  

  • 19. M
    Russell JK; Ingram SM; Teal LB; Lindsley CW; Jones CK
    ACS Chem Neurosci; 2023 Feb; 14(3):435-457. PubMed ID: 36655909
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design and Synthesis of Clinical Candidate PF-06852231 (CVL-231): A Brain Penetrant, Selective, Positive Allosteric Modulator of the M
    Butler CR; Popiolek M; McAllister LA; LaChapelle EA; Kramer M; Beck EM; Mente S; Brodney MA; Brown M; Gilbert A; Helal C; Ogilvie K; Starr J; Uccello D; Grimwood S; Edgerton J; Garst-Orozco J; Kozak R; Lotarski S; Rossi A; Smith D; O'Connor R; Lazzaro J; Steppan C; Steyn SJ
    J Med Chem; 2024 Jul; 67(13):10831-10847. PubMed ID: 38888621
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.